Liu Shi Xin

Nueva
40 años de experiencia
Ubicación: China, Xiamen
Clínica:Hospital Xiamen Humanity
El profesor Shixin Liu, MD, PhD, es el líder de la disciplina del Centro de Oncología. Fue presidente del Hospital Oncológico Provincial de Jilin y director del Instituto de Investigación en Prevención y Tratamiento del Cáncer. Es profesor de nivel II y tutor de doctorado. Ha recibido la Asignación Especial del Gobierno del Consejo de Estado, el 4.º premio Médico Nacional Famoso (Contribución Sobresaliente) y la distinción Modelo de Ética Médica.

Se especializa en el diagnóstico y tratamiento integrales de tumores malignos. Su enfoque es la radioterapia de precisión para cánceres torácicos y abdominales. Domina IMRT, VMAT y SBRT para cáncer de pulmón, esófago, mama y recto.

Sus cargos de liderazgo incluyen la vicepresidencia de Oncología Radioterápica de la CMA, de Radioterapia de la CACA y de Terapia de Partículas de la CACA. Integra el Comité Permanente de la CSCO y es vicepresidente del Comité de Expertos en Oncología Radioterápica de la CSCO. Es vicepresidente de Oncología Radioterápica de la CPAM y miembro del Comité Permanente de la CSMEA. Preside la sección de Oncología Radioterápica de la Asociación Médica de Jilin. Forma parte de los consejos editoriales del Chinese Journal of Radiation Oncology y del Practical Journal of Cancer.
Mostrar más

Nueva

Cita con el médico

Precio a consultar

Bookimed Insights: Principales especialistas en Cáncer de mama en China (2026)

Bookimed ha coordinado 6 solicitudes para el tratamiento de Cáncer de mama en China, colaborando con 1 especialistas de primer nivel. Los médicos en esta tabla se seleccionan por sus credenciales internacionales, experiencia clínica y resultados de pacientes. La clasificación de 2026 se elabora con datos verificados de casos reales y programas actuales de nuestras clínicas asociadas.

Clasificación	Médico	experiencia	Buena opción para	Qué los distingue	Ubicación de la clínica	Consulta

FAQ

Estas preguntas frecuentes provienen de pacientes reales que buscan atención médica a través de Bookimed. Las respuestas son proporcionadas por coordinadores médicos experimentados y representantes autorizados de las clínicas.

Is China a high-quality place for breast cancer treatment?

China offers high-quality breast cancer treatment in JCI-accredited urban centers. Early-stage survival rates exceed 90% in top-tier facilities. Specialized hospitals in Beijing and Shanghai align with international MDT protocols. Advanced technologies like NanoKnife and CyberKnife M6 provide precise, minimally invasive alternatives for complex cases.

Specialized technology: Clinics utilize NanoKnife, cryosurgery, and CyberKnife M6 for targeted tumor destruction.
Survival outcomes: Nationwide 5-year survival is 83.2%, reaching Western standards in major cities.
Accredited facilities: Facilities like Fuda Cancer Hospital maintain JCI accreditation for international safety.
Medical expertise: Doctors like Dr. Leng Yin hold memberships in the Chinese Anti-Cancer Association.

Bookimed Expert Insight: While many seek traditional surgery, China excels in combining immunotherapy with unique ablation techniques. Fuda Cancer Hospital has treated over 30,000 patients from 100 countries using cryosurgery and microwave hyperthermia. This high volume of international cases suggests these specialized protocols are particularly effective for advanced or metastatic breast cancers that require more than standard chemotherapy.

Patient Consensus: Patients note that top-tier urban hospitals provide care rivaling global standards, though they emphasize the need for a translator. Many choose these centers specifically for access to minimally invasive therapies not always available in their home countries.

What advanced therapies are available in China for breast cancer?

Advanced breast cancer therapies in China include next-generation antibody-drug conjugates (ADCs) like Trastuzumab Deruxtecan and Sacituzumab Tirumotecan. Patients access innovative targeted therapies, bispecific antibodies, and specialized radiosurgery. Facilities like Fuda Cancer Hospital utilize minimally invasive techniques and cryosurgery for advanced-stage cases.

Targeted ADCs: Trastuzumab Deruxtecan is approved for HER-2 positive and HER2-low metastatic cases.
Advanced radiation: CyberKnife M6 systems provide precise, non-invasive stereotactic radiosurgery for complex tumors.
Minimally invasive: Clinics offer cryosurgery and NanoKnife as alternatives to traditional intensive chemotherapy.
Novel inhibitors: Bireociclib serves as a unique monotherapy for HR-positive, HER2-negative advanced cancer.

Bookimed Expert Insight: China has emerged as a primary launch market for global oncology innovations. Some ADCs receive regulatory approval here before other major international bodies. For instance, the Jinshazhou Hospital offers CyberKnife M6 treatments for approximately $7,700 (56,000 CNY). This reflects a trend where high-end technology is bundled with comprehensive logistics like clinic transfers.

Patient Consensus: Patients note that top-tier hospitals provide rapid access to clinical trials for metastatic triple-negative cases. They emphasize the importance of using professional coordinators to navigate language barriers and verify legitimate treatments at state-affiliated centers.

Does China offer minimally invasive alternatives to traditional chemotherapy?

China offers advanced minimally invasive breast cancer treatments including NanoKnife, cryosurgery, and vascular interventional therapy. Specialized centers in Guangzhou utilize these technologies to treat tumors without traditional systemic chemotherapy side effects. These methods target cancer cells while preserving surrounding healthy breast tissue and critical structures.

NanoKnife therapy: Uses high-voltage electrical pulses to destroy tumor membranes without heat.
Cryosurgery: Freezes tumors using argon-helium probes for precise, percutaneous cancer destruction.
Interventional therapy: Delivers high-concentration medication directly into tumor blood supplies via micro-catheters.
CyberKnife M6: Provides non-invasive stereotactic radiosurgery for precise tumor targeting with radiation.

Bookimed Expert Insight: Data from Fuda Cancer Hospital shows they apply over 10 types of minimally invasive therapies. A key differentiator in China is the high volume of international patients. Fuda alone has treated over 30,000 patients from 100 countries. This suggests a highly standardized protocol for international cases often missing in smaller regional clinics.

Patient Consensus: Patients note that urban centers like Guangzhou provide better access to breast-conserving options. Many emphasize that having a medical advocate is essential for navigating these specialized Chinese oncology treatments.

Do hospitals in China provide dedicated support for international patients and language assistance?

Major Chinese hospitals provide dedicated support for international patients through specialized International Medical Departments or VIP wings. These units offer bilingual staff, English medical documentation, and streamlined services. Facilities in cities like Guangzhou and Shanghai often hold JCI accreditation to ensure global healthcare standards.

Specialized departments: International Medical Departments (IMD) provide priority access to English-speaking oncologists.
Language support: Leading centers employ multilingual coordinators and AI-powered translation tools for consultations.
Billing services: VIP wings often facilitate direct billing with major global insurance providers.
Care coordination: Dedicated teams manage appointments, medical records, and visa assistance for foreigners.

Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital demonstrate their international focus by treating 30,000 patients from over 100 countries. Data shows that top-tier facilities often employ doctors with extensive global experience. For example, Dr. Leng Yin practiced at major hospitals in Thailand before joining Fuda, ensuring a better understanding of international patient expectations.

Patient Consensus: Patients note that while major cancer centers provide liaison officers and English paperwork, bringing a private interpreter is helpful for complex medical discussions. Many emphasize that using hospital WeChat accounts is the most effective way to coordinate arrival and confirm services beforehand.

Are family members allowed to stay with breast-cancer patients during treatment in China?

Family members are generally allowed to stay with breast cancer patients in China. Most major hospitals permit one designated caregiver to stay overnight in the patient room. Facilities typically provide a folding chair or cot. Access often requires a specific companion card and valid identification like a passport.

Caregiver limit: Most facilities allow only one family member to stay overnight per patient.
Documentation: Caregivers must provide ID or passport copies to receive official hospital companion cards.
Health screening: Hospitals may require negative infection tests or chest X-rays for long-term stayers.
Private rooms: Upgrading to private rooms usually simplifies staying arrangements but involves extra daily fees.

Bookimed Expert Insight: While public hospitals offer basic folding chairs for companions, JCI-accredited centers like Fuda Cancer Hospital in Guangzhou manage high international patient volumes with more supportive structures. Our data shows these facilities often accommodate families better because they are used to patients traveling from over 100 countries. If you are choosing between a tier-3 public ward and a specialized center, the latter is more likely to have established protocols for international family support.

Patient Consensus: Patients note it is essential to bring your own bedding and snacks since hospital provisions for caregivers are often very basic. Many emphasize that having a male relative stay in female wards can sometimes face local restrictions, so confirming specific ward rules early is vital.

How can I obtain a medical visa for breast-cancer treatment in China?

To obtain a medical visa for breast cancer treatment in China, you must secure an official invitation letter from a Grade 3A hospital. Applicants typically require a short-term S2 visa for stays under 180 days. Complex oncology cases exceeding six months require an S1 visa converted into a medical stay permit.

Visa types: S2 visas cover treatments up to 180 days for most oncology patients.
Hospital invitation: Must be issued by a Grade 3A institution with an official stamp.
Medical documentation: Local diagnoses must be officially translated into Chinese for embassy review.
Financial proof: Evidence of $10,000 to $15,000 is typically required to cover treatment costs.

Bookimed Expert Insight: While many search for general medical visas, targeting JCI-accredited facilities like Fuda Cancer Hospital in Guangzhou can simplify the process. These centers manage high international volumes of over 30,000 patients and have established protocols for issuing the specific invitations required by consulates. This institutional experience often reduces the 4–6 week administrative delays common at smaller, non-accredited hospitals.

Patient Consensus: Patients emphasize that paperwork mismatches are common and suggest translating all medical records early. Many note that getting a guarantee from a top-tier hospital is the only way to avoid visa rejection.

Which hospitals are most recommended for breast-cancer treatment in China?

Recommended hospitals for breast cancer in China include Peking Union Medical College Hospital and Fudan University Shanghai Cancer Center. These institutions lead national rankings for multidisciplinary care. Specialized centers like JCI-accredited Fuda Cancer Hospital in Guangzhou offer advanced treatments, including cryosurgery and targeted therapies.

Specialized surgery: Fuda Cancer Hospital provides cryosurgery and NanoKnife for advanced cases.
Leading practitioners: Dr. Leng Yin at Fuda Hospital specializes in complex breast oncology.
Advanced radiation: Jinshazhou Hospital utilizes the CyberKnife M6 system for non-invasive treatments.
Accreditation standards: Top private facilities like Fuda maintain JCI accreditation for international safety.

Bookimed Expert Insight: While public giants like Fudan University Shanghai Cancer Center are prestigious, they often have two-month wait times. International patients find better efficiency at JCI-accredited private centers in Guangzhou. These facilities, such as Fuda Cancer Hospital, manage over 30,000 international cases and prioritize rapid treatment starts.

Patient Consensus: Patients note that top public hospitals are very crowded and may have long waits. Many suggest choosing facilities with dedicated international departments to ensure better communication and faster access to specialists.

Los mejores médicos del tratamiento de Cáncer de mama en Xiamen - TOP-1 médicos

Recibe cotizaciones de 3 de los mejores especialistas en en China